JP2018520100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520100A5 JP2018520100A5 JP2017560182A JP2017560182A JP2018520100A5 JP 2018520100 A5 JP2018520100 A5 JP 2018520100A5 JP 2017560182 A JP2017560182 A JP 2017560182A JP 2017560182 A JP2017560182 A JP 2017560182A JP 2018520100 A5 JP2018520100 A5 JP 2018520100A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- methyl
- azetidine
- difluorophenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 6
- RLGIEZBEUYYQDX-UHFFFAOYSA-N FC1=C(C=CC=C1F)C(C1CNC1)F Chemical compound FC1=C(C=CC=C1F)C(C1CNC1)F RLGIEZBEUYYQDX-UHFFFAOYSA-N 0.000 claims 4
- YDMDKQMLJHBFSZ-UHFFFAOYSA-N FC=1C=C(C=C(C=1)F)C(C1CNC1)F Chemical compound FC=1C=C(C=C(C=1)F)C(C1CNC1)F YDMDKQMLJHBFSZ-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 2
- WTQVUSMOMBOLEV-UHFFFAOYSA-N FC(C1CNC1)C1=C(C(=CC(=C1)F)F)F Chemical compound FC(C1CNC1)C1=C(C(=CC(=C1)F)F)F WTQVUSMOMBOLEV-UHFFFAOYSA-N 0.000 claims 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- -1 3- [fluoro (2,3,5,6-tetrafluorophenyl) methyl] -1-propyl Chemical group 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- FTNGYDNXGAMMLY-UHFFFAOYSA-N C(C)N1CC(C1)C(C1=C(C(=C(C=C1)F)F)F)F Chemical compound C(C)N1CC(C1)C(C1=C(C(=C(C=C1)F)F)F)F FTNGYDNXGAMMLY-UHFFFAOYSA-N 0.000 claims 1
- XEQDOSZVDJYSBE-UHFFFAOYSA-N C(C)N1CC(C1)C(C1=C(C(=CC(=C1)F)F)F)F Chemical compound C(C)N1CC(C1)C(C1=C(C(=CC(=C1)F)F)F)F XEQDOSZVDJYSBE-UHFFFAOYSA-N 0.000 claims 1
- WHJQAOWPASSDBM-UHFFFAOYSA-N C(C)N1CC(C1)C(C1=C(C(=CC(=C1F)F)F)F)F Chemical compound C(C)N1CC(C1)C(C1=C(C(=CC(=C1F)F)F)F)F WHJQAOWPASSDBM-UHFFFAOYSA-N 0.000 claims 1
- BFRSONMVYVLBCJ-UHFFFAOYSA-N C(C)N1CC(C1)C(C1=CC(=C(C(=C1)F)F)F)F Chemical compound C(C)N1CC(C1)C(C1=CC(=C(C(=C1)F)F)F)F BFRSONMVYVLBCJ-UHFFFAOYSA-N 0.000 claims 1
- 210000003710 Cerebral Cortex Anatomy 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- NMVQEWYTYLQGIC-UHFFFAOYSA-N FC(C1CN(C1)C)C1=C(C(=CC(=C1)F)F)F Chemical compound FC(C1CN(C1)C)C1=C(C(=CC(=C1)F)F)F NMVQEWYTYLQGIC-UHFFFAOYSA-N 0.000 claims 1
- RBQJTFPBFGWHEP-UHFFFAOYSA-N FC(C1CN(C1)C)C1=C(C(=CC(=C1F)F)F)F Chemical compound FC(C1CN(C1)C)C1=C(C(=CC(=C1F)F)F)F RBQJTFPBFGWHEP-UHFFFAOYSA-N 0.000 claims 1
- BJMGXOXVJQBUQB-UHFFFAOYSA-N FC(C1CN(C1)CCC)C1=C(C(=C(C=C1)F)F)F Chemical compound FC(C1CN(C1)CCC)C1=C(C(=C(C=C1)F)F)F BJMGXOXVJQBUQB-UHFFFAOYSA-N 0.000 claims 1
- VNKVDNKPSHRUKF-UHFFFAOYSA-N FC(C1CN(C1)CCC)C1=C(C(=CC(=C1)F)F)F Chemical compound FC(C1CN(C1)CCC)C1=C(C(=CC(=C1)F)F)F VNKVDNKPSHRUKF-UHFFFAOYSA-N 0.000 claims 1
- SNZSYPBGUMRPTN-UHFFFAOYSA-N FC(C1CN(C1)CCC)C1=CC(=C(C(=C1)F)F)F Chemical compound FC(C1CN(C1)CCC)C1=CC(=C(C(=C1)F)F)F SNZSYPBGUMRPTN-UHFFFAOYSA-N 0.000 claims 1
- ZPMFWTHAKBDOCH-UHFFFAOYSA-N FC(C1CNC1)C1=C(C(=C(C(=C1F)F)F)F)F Chemical compound FC(C1CNC1)C1=C(C(=C(C(=C1F)F)F)F)F ZPMFWTHAKBDOCH-UHFFFAOYSA-N 0.000 claims 1
- MWJYYOBBMFUUNS-UHFFFAOYSA-N FC(C1CNC1)C1=C(C(=C(C=C1)F)F)F Chemical compound FC(C1CNC1)C1=C(C(=C(C=C1)F)F)F MWJYYOBBMFUUNS-UHFFFAOYSA-N 0.000 claims 1
- NTUHFENJADPVRW-UHFFFAOYSA-N FC(C1CNC1)C1=C(C(=CC(=C1F)F)F)F Chemical compound FC(C1CNC1)C1=C(C(=CC(=C1F)F)F)F NTUHFENJADPVRW-UHFFFAOYSA-N 0.000 claims 1
- NWMOZJOGEBCIQV-UHFFFAOYSA-N FC(C1CNC1)C1=C(C=C(C=C1F)F)F Chemical compound FC(C1CNC1)C1=C(C=C(C=C1F)F)F NWMOZJOGEBCIQV-UHFFFAOYSA-N 0.000 claims 1
- HJCSYUVYTGEWAB-UHFFFAOYSA-N FC(C1CNC1)C1=CC(=C(C(=C1)F)F)F Chemical compound FC(C1CNC1)C1=CC(=C(C(=C1)F)F)F HJCSYUVYTGEWAB-UHFFFAOYSA-N 0.000 claims 1
- USVFTDDWEILBOY-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)C(C1CNC1)F Chemical compound FC1=C(C(=CC=C1)F)C(C1CNC1)F USVFTDDWEILBOY-UHFFFAOYSA-N 0.000 claims 1
- ICKIYYSZXUBAQT-UHFFFAOYSA-N FC1=C(C=C(C=C1)F)C(C1CNC1)F Chemical compound FC1=C(C=C(C=C1)F)C(C1CNC1)F ICKIYYSZXUBAQT-UHFFFAOYSA-N 0.000 claims 1
- LCRBUJUHACXMJU-UHFFFAOYSA-N FC1=C(C=CC(=C1)F)C(C1CNC1)F Chemical compound FC1=C(C=CC(=C1)F)C(C1CNC1)F LCRBUJUHACXMJU-UHFFFAOYSA-N 0.000 claims 1
- ODGXGHOVJREFHT-UHFFFAOYSA-N FC1=C(C=CC=C1F)C(C1CN(C1)C)F Chemical compound FC1=C(C=CC=C1F)C(C1CN(C1)C)F ODGXGHOVJREFHT-UHFFFAOYSA-N 0.000 claims 1
- YGDYMJPPXULCSV-UHFFFAOYSA-N FC1=C(C=CC=C1F)C(C1CN(C1)CC)F Chemical compound FC1=C(C=CC=C1F)C(C1CN(C1)CC)F YGDYMJPPXULCSV-UHFFFAOYSA-N 0.000 claims 1
- CSSSEKRPTRLVBB-UHFFFAOYSA-N FC1=C(C=CC=C1F)C(C1CN(C1)CCC)F Chemical compound FC1=C(C=CC=C1F)C(C1CN(C1)CCC)F CSSSEKRPTRLVBB-UHFFFAOYSA-N 0.000 claims 1
- AFHILXSUEZSRIJ-UHFFFAOYSA-N FC=1C=C(C=C(C=1)F)C(C1CN(C1)C)F Chemical compound FC=1C=C(C=C(C=1)F)C(C1CN(C1)C)F AFHILXSUEZSRIJ-UHFFFAOYSA-N 0.000 claims 1
- RTIAMFGRZZLFLE-UHFFFAOYSA-N FC=1C=C(C=C(C=1)F)C(C1CN(C1)CC)F Chemical compound FC=1C=C(C=C(C=1)F)C(C1CN(C1)CC)F RTIAMFGRZZLFLE-UHFFFAOYSA-N 0.000 claims 1
- ARSZGWXOGYCISK-UHFFFAOYSA-N FC=1C=C(C=C(C=1)F)C(C1CN(C1)CCC)F Chemical compound FC=1C=C(C=C(C=1)F)C(C1CN(C1)CCC)F ARSZGWXOGYCISK-UHFFFAOYSA-N 0.000 claims 1
- WXDJCYFXUACOQL-UHFFFAOYSA-N FC=1C=C(C=CC=1F)C(C1CNC1)F Chemical compound FC=1C=C(C=CC=1F)C(C1CNC1)F WXDJCYFXUACOQL-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000007185 autism spectrum disease Diseases 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 201000008895 mood disease Diseases 0.000 claims 1
- 201000009457 movement disease Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 0 CC(/C(/C/C(/C(*)C1CN(*)C1)=C\C1)=C/C=*1/F)F Chemical compound CC(/C(/C/C(/C(*)C1CN(*)C1)=C\C1)=C/C=*1/F)F 0.000 description 14
Claims (18)
- nは0または1である、請求項1に記載の化合物またはその薬学的に許容される塩。
- R4はFである、請求項1〜6のいずれか1項に記載の化合物またはその薬学的に許容される塩。
- R5はHである、請求項1〜7のいずれか1項に記載の化合物またはその薬学的に許容される塩。
- (−)−3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
(+)−3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
(−)−3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
(+)−3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[(3,4−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[(2,5−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[(2,6−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[(2,4−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[フルオロ(2,3,5−トリフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(2,4,6−トリフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(2,3,4−トリフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(3,4,5−トリフルオロフェニル)メチル]アゼチジン、
3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]アゼチジン、
3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]−1−メチルアゼチジ ン、
3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]−1−エチルアゼチジン、
3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]−1−プロピルアゼチジン、
3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]−1−メチルアゼチジン、
3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]−1−エチルアゼチジン、
3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]−1−プロピルアゼチジン、
3−[フルオロ(2,3,5−トリフルオロフェニル)メチル]−1−メチルアゼチジン、
1−エチル−3−[フルオロ(2,3,5−トリフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(2,3,5−トリフルオロフェニル)メチル]−1−プロピルアゼチジン、
1−エチル−3−[フルオロ(2,3,4−トリフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(2,3,4−トリフルオロフェニル)メチル]−1−プロピルアゼチジン、
1−エチル−3−[フルオロ(3,4,5−トリフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(3,4,5−トリフルオロフェニル)メチル]−1−プロピルアゼチジン、
3−[フルオロ(2,3,5,6−テトラフルオロルフェニル)メチル]アゼチジン、
3−[フルオロ(ペンタフルオロフェニル)メチル]アゼチジン、
3−[フルオロ(2,3,5,6−テトラフルオロフェニル)メチル]−1−メチルアゼチジン、
1−エチル−3−[フルオロ(2,3,5,6−テトラフルオロフェニル)メチル]−アゼチジン、および
3−[フルオロ(2,3,5,6−テトラフルオロフェニル)メチル]−1−プロピルアゼチジンである、請求項1に記載の化合物、または前述の化合物のいずれかの薬学的に許容される塩。 - (−)−3−[(2,3−ジフルオロフェニル)(フルオロ)メチル]アゼチジンである、請求項1に記載の化合物、または前述の化合物のいずれかの薬学的に許容される塩。
- (−)−3−[(3,5−ジフルオロフェニル)(フルオロ)メチル]アゼチジンである、請求項1に記載の化合物、または前述の化合物のいずれかの薬学的に許容される塩。
- (−)−3−[フルオロ(2,3,5−トリフルオロフェニル)メチル]アゼチジンである、請求項1に記載の化合物、または前述の化合物のいずれかの薬学的に許容される塩。
- 式Iの化合物は(−)−エナンチオマーである、請求項1〜12のいずれか1項に記載の化合物またはその薬学的に許容される塩。
- 化合物が、重水素、トリチウム、11C、14C、18O、17O、19Fおよび18Fからなる群から選択される同位体で標識化される、請求項1〜13のいずれか1項に記載の化合物またはその薬学的に許容される塩。
- 請求項1〜14のいずれか1項に記載の化合物またはその薬学的に許容される塩の治療有効量を、少なくとも1種の薬学的に許容される担体、賦形剤および/または希釈剤と一緒に含む医薬組成物。
- 医薬としての使用のための、請求項1〜14のいずれか1項に記載の化合物または薬学的に許容される塩。
- 大脳皮質におけるモノアミンのモジュレーションに応答性を有する疾患、障害および/または状態の処置および/または予防のための医薬の製造のための、請求項1〜14のいずれか1項に記載の化合物の使用であって、前記疾患、障害および/または状態は、認知症、年齢関連性認知機能欠損、神経変性障害および/または神経変性疾患に関連する認知機能欠損、自閉症スペクトラム障害、感情障害、統合失調症、不安障害、注意欠陥多動性障害(ADHD)ならびに動作障害からなる群から選択される、前記使用。
- 前記疾患、障害および/または状態は、認知症、年齢関連性認知機能欠損および統合失調症からなる群から選択される、請求項17に記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15168373.7 | 2015-05-20 | ||
EP15168373 | 2015-05-20 | ||
SE1650485-4 | 2016-04-11 | ||
SE1650485 | 2016-04-11 | ||
PCT/EP2016/061479 WO2016185032A1 (en) | 2015-05-20 | 2016-05-20 | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018520100A JP2018520100A (ja) | 2018-07-26 |
JP2018520100A5 true JP2018520100A5 (ja) | 2019-05-09 |
JP6679621B2 JP6679621B2 (ja) | 2020-04-15 |
Family
ID=56026881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560182A Active JP6679621B2 (ja) | 2015-05-20 | 2016-05-20 | 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規なアゼチジン誘導体 |
Country Status (18)
Country | Link |
---|---|
US (2) | US10087142B2 (ja) |
EP (1) | EP3297987B1 (ja) |
JP (1) | JP6679621B2 (ja) |
KR (1) | KR102595892B1 (ja) |
CN (1) | CN107646031B (ja) |
AU (1) | AU2016263510B2 (ja) |
CA (1) | CA2985710C (ja) |
DK (1) | DK3297987T3 (ja) |
ES (1) | ES2730890T3 (ja) |
HK (1) | HK1245251B (ja) |
IL (1) | IL255618B (ja) |
MX (1) | MX365283B (ja) |
NZ (1) | NZ737451A (ja) |
PL (1) | PL3297987T3 (ja) |
PT (1) | PT3297987T (ja) |
RU (1) | RU2716814C2 (ja) |
WO (1) | WO2016185032A1 (ja) |
ZA (1) | ZA201707936B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3297987T (pt) * | 2015-05-20 | 2019-06-19 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
PT3541784T (pt) * | 2016-11-18 | 2023-11-22 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1512969A1 (ru) * | 1988-02-01 | 1989-10-07 | Институт нефтехимического синтеза им.А.В.Топчиева | Способ получени N-алкилазетидинов |
FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
KR20100038295A (ko) * | 2007-06-05 | 2010-04-14 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘 |
AU2009317155A1 (en) * | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
US20110257148A1 (en) * | 2008-11-24 | 2011-10-20 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
DK2367787T3 (da) * | 2008-11-24 | 2013-03-25 | Nsab Af Neurosearch Sweden Ab | 3-phenyl-3-methoxypyrrolidinderivater som modulatorer af kortikal katekolaminerg neurotransmission |
KR101273566B1 (ko) * | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
PT3297987T (pt) * | 2015-05-20 | 2019-06-19 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
-
2016
- 2016-05-20 PT PT16724046T patent/PT3297987T/pt unknown
- 2016-05-20 JP JP2017560182A patent/JP6679621B2/ja active Active
- 2016-05-20 PL PL16724046T patent/PL3297987T3/pl unknown
- 2016-05-20 CN CN201680027679.0A patent/CN107646031B/zh active Active
- 2016-05-20 CA CA2985710A patent/CA2985710C/en active Active
- 2016-05-20 AU AU2016263510A patent/AU2016263510B2/en active Active
- 2016-05-20 EP EP16724046.4A patent/EP3297987B1/en active Active
- 2016-05-20 WO PCT/EP2016/061479 patent/WO2016185032A1/en active Application Filing
- 2016-05-20 KR KR1020177033560A patent/KR102595892B1/ko active IP Right Grant
- 2016-05-20 US US15/574,796 patent/US10087142B2/en active Active
- 2016-05-20 ES ES16724046T patent/ES2730890T3/es active Active
- 2016-05-20 RU RU2017140419A patent/RU2716814C2/ru active
- 2016-05-20 MX MX2017014577A patent/MX365283B/es active IP Right Grant
- 2016-05-20 DK DK16724046.4T patent/DK3297987T3/da active
- 2016-05-20 NZ NZ737451A patent/NZ737451A/en unknown
-
2017
- 2017-11-13 IL IL255618A patent/IL255618B/en active IP Right Grant
- 2017-11-22 ZA ZA2017/07936A patent/ZA201707936B/en unknown
-
2018
- 2018-04-04 HK HK18104487.2A patent/HK1245251B/zh unknown
- 2018-09-27 US US16/144,076 patent/US10287247B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000036A1 (es) | Derivados etinilo | |
JP2017521387A5 (ja) | ||
JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
JP2013507369A5 (ja) | ||
MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
EA201500402A1 (ru) | Гетероароматические соединения в качестве лигандов допамина d1 | |
JP2009531404A5 (ja) | ||
JP2015516420A5 (ja) | ||
AR071054A1 (es) | Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa. | |
JP2009538910A5 (ja) | ||
JP2015508092A5 (ja) | ||
JP2010530403A5 (ja) | ||
JP2013507374A5 (ja) | ||
JP2018520100A5 (ja) | ||
PH12016501100A1 (en) | Ethynyl-imidazolin-2, 4-dione derivatives as mglur4 modulators | |
JP2016514100A5 (ja) | ||
MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
JP2016522254A5 (ja) | ||
JP2017520540A5 (ja) | ||
JP2013511511A5 (ja) | ||
JP2021504326A5 (ja) | ||
JP2015531764A5 (ja) | ||
HRP20160128T1 (hr) | Terapeutska sredstva 713 | |
RU2533819C2 (ru) | Синтез и новые солевые формы (r)-5-((e)-2-(пирролидин-3-илвинил)пиримидина | |
JP2017507980A5 (ja) |